Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: J Clin Densitom. 2017 Jun 16;20(4):507–512. doi: 10.1016/j.jocd.2017.05.007

Table 1.

Baseline characteristics (mean (SD) or number (%)). DXA=dual x-ray absorptiometry. There were no significant differences among the three groups for all characteristics.

Teriparatide to denosumab
(N=25)		 Denosumab to teriparatide
(N=22)		 Combination to denosumab
(N=18)
Age (years) 65.2 (6.3) 63.9 (6.2) 64.5 (7.4)
Body-mass index (kg/m2) 25.7 (3.6) 23.4 (4.0) 25.6 (5.3)
White, non-Hispanic 25 (100%) 20 (91%) 15 (83%)
Clinical fracture at age >45 years (%) 13 (52%) 6 (27%) 3 (17%)
DXA posterior-anterior spine (g/cm2) 0.815 (0.109) 0.853 (0.101) 0.828 (0.130)
Trabecular bone score 1.27 (0.10) 1.31 (0.09) 1.26 (0.08)